Sclerosis News and Research RSS Feed - Sclerosis News and Research

55% of people with dementia have never seen a doctor, shows study

55% of people with dementia have never seen a doctor, shows study

The majority of people with dementia have never seen a doctor about their memory and thinking problems, according to a new study published in the November 26, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]
Cedars-Sinai Medical Center releases November tip sheet of story ideas

Cedars-Sinai Medical Center releases November tip sheet of story ideas

Following is the November 2014 tip sheet of story ideas from Cedars-Sinai Medical Center. [More]
PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

PPMD, Santhera Pharmaceuticals collaborate to study Duchenne muscular dystrophy

Parent Project Muscular Dystrophy, the leading advocacy organization working to end Duchenne muscular dystrophy (Duchenne) and Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases, will collaborate on a benefit/risk study in Duchenne. [More]
Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A. [More]
Dantrolene drug may be effective treatment for rare form of diabetes

Dantrolene drug may be effective treatment for rare form of diabetes

A commonly prescribed muscle relaxant may be an effective treatment for a rare but devastating form of diabetes, researchers at Washington University School of Medicine in St. Louis report. [More]
NUS researchers make breakthrough discovery that could lead to future treatment for multiple sclerosis

NUS researchers make breakthrough discovery that could lead to future treatment for multiple sclerosis

A multi-disciplinary research team from the National University of Singapore has made a breakthrough discovery of a new type of immune cells that may help in the development of a future treatment for multiple sclerosis (MS). [More]
Research paves way for improving efficacy of ALS treatement

Research paves way for improving efficacy of ALS treatement

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis. Currently ALS has no cure. Despite promising early-stage research, the majority of drugs in development for ALS have failed. Now researchers have uncovered a possible explanation. [More]
People who handle complex jobs may have longer-lasting memory and thinking abilities

People who handle complex jobs may have longer-lasting memory and thinking abilities

People whose jobs require more complex work with other people, such as social workers and lawyers, or with data, like architects or graphic designers, may end up having longer-lasting memory and thinking abilities compared to people who do less complex work, according to research published in the November 19, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Vitamin B12, folic acid supplements may not reduce risk of memory and thinking problems

Vitamin B12, folic acid supplements may not reduce risk of memory and thinking problems

Taking vitamin B12 and folic acid supplements may not reduce the risk of memory and thinking problems after all, according to a new study published in the November 12, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. The study is one of the largest to date to test long-term use of supplements and thinking and memory skills. [More]
Researchers identify key protein that can reduce severity of disease equivalent to MS in mice

Researchers identify key protein that can reduce severity of disease equivalent to MS in mice

In multiple sclerosis, the immune system goes rogue, improperly attacking the body's own central nervous system. Mobility problems and cognitive impairments may arise as the nerve cells become damaged. [More]
Study points to major role of obesity in triggering, prolonging autoimmune diseases

Study points to major role of obesity in triggering, prolonging autoimmune diseases

Autoimmune diseases like Crohn's Disease and multiple sclerosis, in which the immune system attacks its own body rather than predatory invaders, affect 5-20% of the global community. A study published recently in Autoimmunity Reviews by Prof. Yehuda Shoenfeld, the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at Tel Aviv University's Sackler Faculty of Medicine and Head of Zabludowicz Center for Autoimmune Diseases at Chaim Sheba Medical Center, Tel Hashomer, points to the major role obesity plays in triggering and prolonging these autoimmune diseases. [More]
U of T, Chematria and IBM partner to find new treatments for Ebola virus

U of T, Chematria and IBM partner to find new treatments for Ebola virus

The University of Toronto, Chematria and IBM are combining forces in a quest to find new treatments for the Ebola virus. [More]

Perrigo agrees to acquire Omega for $4.5 billion

Perrigo Company plc, a leading global provider of "Quality Affordable Healthcare Products," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for €3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for €2.48 billion and the assumption of €1.1 billion in debt. [More]

Perrigo re-launches shipments of Guaifenesin 600mg Extended-Release tablets

Perrigo Company plc announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets. [More]
Epilepsy: A true window on the brain

Epilepsy: A true window on the brain

Rapidly emerging technologies, novel imaging techniques, the development of new therapies and new genes, have given researchers and clinicians an extraordinary ability to explore the brain at the cellular, genetic and neural levels. While current epilepsy research may seem like it's ripped from the pages of a science fiction novel, it's real—and even pretty cool. [More]
Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Commonly prescribed drugs for arthritis and pain may increase risk of death from stroke

Commonly prescribed, older drugs for arthritis and pain may increase the risk of death from stroke, according to a study published in the November 5, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology. Stroke is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention. [More]
Medical illness common in bipolar disorder

Medical illness common in bipolar disorder

Patients with bipolar disorder have high rates of medical illness, which often exceeds the levels observed in patients with unipolar depression, show results of a UK-based study. [More]
Scientists uncover small set of genes critical in aging and neurodegenerative disease

Scientists uncover small set of genes critical in aging and neurodegenerative disease

Aging is the most significant and universal risk factor for developing neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's, Parkinson's and Huntington's diseases. This risk increases disproportionately with age, but no one really knows why. [More]
Hemp Health launches CBD wellness supplements

Hemp Health launches CBD wellness supplements

Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness supplements. Available in oil, spray and capsule form, Hemp Health's products offer a compelling alternative to medical marijuana. The CBD supplements provide consumers with the therapeutic ingredient in hemp while allowing them to avoid the negative mental and physical effects of marijuana. [More]

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announces that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has given a positive opinion on the designation of IVA337 as an orphan medicinal product. [More]